파이프라인
| Platform | Project | Theraqeutics | Indication | R&D | Preclinical | Phase I | Phase II | NDA |
|---|---|---|---|---|---|---|---|---|
| TIL | NEOG-100 | TIL (Tumor Infiltrating Lymphocyte) |
Solid tumor (TNBC, NSCLC) |
|
||||
| TIL | NEOG-110 | Neoantigen reactive Tumor Infiltrating Lymphocyte |
Solid tumor |
|
||||
| TIL | NEOG-2000 | Gene transferred Tumor Infiltrating Lymphocyte |
Solid cancer |
|
||||
| TCR-T | NEOG-4000 | Private Neoantigen specific TCR engineered T (TCR-T) cell |
Solid tumor |
|
||||
| TCR-T | Transposon system | Gene engineering system |
|
-
NEOG-100
-
Theraqeutics
TIL
(Tumor Infiltrating Lymphocyte) -
Indication
Solid tumor
(TNBC, NSCLC)
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
NEOG-110
-
Theraqeutics
Neoantigen reactive
Tumor Infiltrating Lymphocyte -
Indication
Solid tumor
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
NEOG-2000
-
Theraqeutics
Gene transferred
Tumor Infiltrating Lymphocyte -
Indication
Solid cancer
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
Transposon system
-
Theraqeutics
Gene engineering system -
Indication
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
NEOG-4000
-
Theraqeutics
Private Neoantigen specific
TCR engineered T (TCR-T) cell -
Indication
Solid tumor
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-